Navigation Links
Vermillion Reports Second Quarter 2012 Results
Date:8/14/2012

y of OVA1 combined with clinical assessment at 96% for a broad range of adnexal malignancies, with 91% sensitivity for early-stage ovarian cancer (stage I and II). Overall NPV was 98%, a substantial improvement from the previously reported value of 95%. Overall combined specificity was also higher, at 51% in this intended use population, and OVA1 showed 61% specificity as a risk stratification tool in pre-menopausal women. These results independently confirm and extend the evidence of OVA1's clinical utility in the presurgical detection and management of adnexal malignancies.

Q2 2012 Financial Highlights
Total revenue in the second quarter of 2012 was $321,000, comprised of $208,000 in OVA1 sales and $113,000 in license fees from Quest Diagnostics. Product revenue from OVA1 sales in the second quarter of 2012 represented an increase of 9% compared to $191,000 in the same year-ago quarter.

Total operating expenses decreased in the second quarter of 2012 to $4.0 million from $5.9 million in the same period a year ago. The second quarter of 2012 included $0.4 million in non-cash stock-based compensation as compared to $1.3 million in the same year-ago quarter. The remainder of the decrease was due primarily to the company's restructuring program announced in January 2012, as well as lower clinical trial costs as compared to the same year-ago quarter. For the six months ended June 30, 2012, total operating expenses were $6.4 million as compared to $10.7 million in the same year-ago period.

Net loss for the second quarter was $2.0 million or $(0.13) per share as compared to $5.7 million or $(0.39) per share in the same year-ago quarter. The second quarter of 2012 net loss included a $1.8 million gain from the release of an escrow account related to our 2006 sale of the instrument business. For the six months ended June 30, 2012, net loss was $3.8 million or $(0.25) per share as compared to $10.0 million or $(0.73) per share in the same year-ago p
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
2. Vermillion Announces CEO Succession Plan
3. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
4. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
5. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
6. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
7. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
8. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
9. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... and BOSTON , September 16, 2014 ... Scientific Officer, Fiona Marshall , will give a presentation ... protein-coupled receptors using StaR ®   technology ... in Drug Discovery and Development " virtual symposium run by ... Society. The virtual symposium is on Wednesday, 24 September 2014; ...
(Date:9/15/2014)... , Sept. 16, 2014 The French ... (HNF) announced today an agreement to collaborate on programs ... support the development of a stronger CMT patient and ... support to several HNF,s initiatives including: , ... the HNF website featuring  HNF newsletters, materials and latest ...
(Date:9/15/2014)... Sept. 16, 2014  Bayer HealthCare and Orion ... Finland , have begun to enroll ... an investigational oral androgen receptor inhibitor in clinical ... men with castration-resistant prostate cancer who have rising ... metastases. The trial is designed to determine the ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... Nov. 5, 2010 EnVivo Pharmaceuticals today announced it ... agonist, possesses a novel mechanism not previously seen in ... Acetylcholine (ACh) to enhance cognition. By acting ... makes it possible for smaller amounts of naturally occurring ...
... Nov. 5, 2010 Cadence Pharmaceuticals, Inc. (Nasdaq: ... developing and commercializing proprietary product candidates principally for use ... the three and nine months ended September 30, 2010. ... U.S. Food and Drug Administration (FDA) approved OFIRMEV™ (acetaminophen) ...
Cached Medicine Technology:EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 3Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 2Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 3Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 4Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 5Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 6
(Date:9/16/2014)... QuickMedical, a national leader in the ... veteran-owned small business has officially launched three new ... Nipro Medical, and CP Medical Sutures. , ... best, most affordable medical equipment and supplies. To ... effort to reach new medical facilities, QuickMedical has ...
(Date:9/16/2014)... Richmond, VA (PRWEB) September 16, 2014 ... Museum of Virginia this fall. Reflecting on what it ... Ethics: Expanding Community Vision investigates unique and thought-provoking topics. ... people to be inspired to look at their world ... provoking and set the stage for truly enlightening dialogue,” ...
(Date:9/16/2014)... Today, the Diamond in the Raw Foundation ... held, Sunday, October 19, 2014 at the Skirball Cultural ... show honors the dare-devil stuntwomen of film and television ... Over 12 categories will be recognized in the two-hour ... , Special honors will be given to legendary stuntwomen ...
(Date:9/16/2014)... N.C. (PRWEB) September 16, 2014 Triad ... President & CEO of Intersil and former President of ... of directors. , “David has extraordinary technology and business ... Triad’s board of directors,” said Lynn Hayden, Triad CEO ... years of analog and mixed signal semiconductor experience to ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 A peep-toe ... back, bootie, or any other dress shoe) in which ... the toes to show. Peep-toe shoes were popular beginning ... shoes had a brief resurgence in the 1970s/80s, before ... they have enjoyed some popularity again, with variations such ...
Breaking Medicine News(10 mins):Health News:Expanding Community Vision at the Science Museum of Virginia 2Health News:Hollywood's Action Icon Awards to Honor Legendary Stuntwomen In A Star-Studded Gala and Awards Ceremony 2Health News:David Bell Joins Triad Semiconductor's Board of Directors 2Health News:Nice Peep Toes Are For Sale At Fecbek.com 2
... THURSDAY, Dec. 15 (HealthDay News) -- Lack of time is ... suggests that several short intensive workouts a week may help ... regimens. The small, new study found that 30 ... time of 75 minutes a week with warm-up and cool-down ...
... -- Nearly 20 million Americans who see a dentist at ... general health care provider, which suggests that dentists could screen ... pressure, diabetes and heart disease, a new study says. ... adults who took part in the 2008 U.S. National Health ...
... , THURSDAY, Dec. 15 (HealthDay News) - To catch cervical ... human papillomavirus (HPV) test is the best option for women ... with the more traditional Pap smear resulted in earlier detection ... developing, said study author Dr. Chris Meijer, a professor of ...
... researchers at the University of Alberta have discovered a new ... those living with the disease, by using a powerful, triple ... brain tissue. The researchers discovered that iron levels in ... brain that are responsible for relaying messages. High iron levels ...
... coffee maker, and the simple quest becomes, well, an ordeal. After ... you finally make a purchase, only to wonder: "Was this the ... Reality check: Is this you? If so, new research ... to make a decision that you,ll be happy with. Joyce ...
... (HealthDay News) -- Low levels of iron in the blood ... that form in a vein, according to the results of ... vessel disease. The findings suggest that treating iron deficiency ... (DVT), according to the researchers at Imperial College London in ...
Cached Medicine News:Health News:Brief, Intense Exercise Lowers Blood Sugar, Small Study Finds 2Health News:Brief, Intense Exercise Lowers Blood Sugar, Small Study Finds 3Health News:Dentists Could Fill Gap in Health Care, Study Says 2Health News:HPV Test Spots Cervical Cancer Earlier Than Pap Smear: Study 2Health News:HPV Test Spots Cervical Cancer Earlier Than Pap Smear: Study 3Health News:Using powerful MRI to track iron levels in brain could be new way to monitor progression of MS 2Health News:Psychology researcher finds that second-guessing one's decisions leads to unhappiness 2Health News:Psychology researcher finds that second-guessing one's decisions leads to unhappiness 3Health News:Low Iron Levels May Increase Blood Clot Risk 2
The ELISA test is used for detection and semi quantitation of igG antibodies to proteinase 3(PR3) in human sera, as an aid to the diagnosis is of Wegener's granulomatosis....
... Acolytes core technology relates to the ultrasensitive ... found in all living cells. ATP ... using bioluminescence. By coupling AK ... via extraction using antibody-coated beads, Acolyte can ...
... DYONICS POWERMAX Shaver Handpiece has 25% more ... standard Smith & Nephew handpiece providing optimal ... handling and reduced hand fatigue. ,The forward/reverse ... suction lever are all co-located to allow ...
... tailored to individual needs. The pump can ... Indeed a Shaver unit only is featured ... and handpiece.,The REVOLUTION shaver system features a ... progressive motor (up to 4.000 rpm). When ...
Medicine Products: